4
Participants
Start Date
March 20, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Avonex (IFNβ-1-a, Biogen Netherlands B.V)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Rebif (IFNβ-1-a, Merck Europe B.V.)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Extavia (IFNβ-1-b, Novartis Europharm Limited)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
MS disease modifying drugs (MSDMDs)
Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
Many locations, Multiple Locations
Many locations, Multiple Locations
Lead Sponsor
Biogen Netherlands B.V
UNKNOWN
Novartis Europharm Limited
UNKNOWN
Merck Europe B.V.
UNKNOWN
Bayer
INDUSTRY